Photo from wikipedia
Prevention, both primary and secondary, was in the spotlight of this years American Heart Association (AHA) Scientific Sessions held in freezing Chicago in early November. Two late-breaking clinical trials sessions… Click to show full abstract
Prevention, both primary and secondary, was in the spotlight of this years American Heart Association (AHA) Scientific Sessions held in freezing Chicago in early November. Two late-breaking clinical trials sessions were dedicated to the field of prevention, covering several fields including inflammation reduction as a therapeutic means in atherosclerotic cardiovascular disease (ASCVD) prevention, the presentation of the third sodium-dependent glucose transporter-2 (SGLT-2) inhibitor phase III outcome trial and most importantly, the vast field of lipidology, from low-density lipoprotein (LDL)-lowering agents, somewhat surprising results in the omega-3 field to the new North American guideline on the management of blood cholesterol.
Journal Title: European Journal of Preventive Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!